Malignant Pleural Mesothelioma-Pipeline Review, H2 2015

Malignant Pleural Mesothelioma-Pipeline Review, H2 2015

  • Products Id :- GMDHC7231IDB
  • |
  • Pages: 248
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Malignant Pleural Mesothelioma-Pipeline Review, H2 2015


Global Markets Direct's, 'Malignant Pleural Mesothelioma-Pipeline Review, H2 2015', provides an overview of the Malignant Pleural Mesothelioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Malignant Pleural Mesothelioma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Malignant Pleural Mesothelioma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Malignant Pleural Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Malignant Pleural Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Malignant Pleural Mesothelioma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Malignant Pleural Mesothelioma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 9

Introduction 10

Global Markets Direct Report Coverage 10

Malignant Pleural Mesothelioma Overview 11

Therapeutics Development 12

Pipeline Products for Malignant Pleural Mesothelioma-Overview 12

Pipeline Products for Malignant Pleural Mesothelioma-Comparative Analysis 13

Malignant Pleural Mesothelioma-Therapeutics under Development by Companies 14

Malignant Pleural Mesothelioma-Therapeutics under Investigation by Universities/Institutes 16

Malignant Pleural Mesothelioma-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Malignant Pleural Mesothelioma-Products under Development by Companies 20

Malignant Pleural Mesothelioma-Products under Investigation by Universities/Institutes 23

Malignant Pleural Mesothelioma-Companies Involved in Therapeutics Development 24

Aduro BioTech, Inc. 24

Advantagene, Inc. 25

Amphera BV 26

AnGes MG, Inc. 27

ArQule, Inc. 28

Bayer AG 29

Biogen, Inc. 30

Bionomics Limited 31

Boehringer Ingelheim GmbH 32

Boston Biomedical, Inc. 33

Bristol-Myers Squibb Company 34

CanBas Co., Ltd. 35

Concordia Healthcare Corp. 36

EnGeneIC Ltd 37

F. Hoffmann-La Roche Ltd. 38

Five Prime Therapeutics, Inc. 39

Genelux Corporation 40

GlaxoSmithKline Plc 41

Juno Therapeutics Inc. 42

MedImmune, LLC 43

Merck & Co., Inc. 44

MolMed S.p.A. 45

Morphotek, Inc. 46

Novartis AG 47

Ono Pharmaceutical Co., Ltd. 48

Oxford BioMedica Plc 49

Pfizer Inc. 50

Pharma Mar, S.A. 51

Polaris Pharmaceuticals, Inc. 52

Synta Pharmaceuticals Corp. 53

Verastem, Inc. 54

Virttu Biologics Limited 55

Malignant Pleural Mesothelioma-Therapeutics Assessment 56

Assessment by Monotherapy Products 56

Assessment by Target 57

Assessment by Mechanism of Action 59

Assessment by Route of Administration 61

Assessment by Molecule Type 63

Drug Profiles 65

Ad5-SGE-REIC/Dkk3-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

amatuximab-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

anetumab ravtansine-Drug Profile 70

Product Description 70

Mechanism of Action 70

R&D Progress 70

ascrinvacumab-Drug Profile 72

Product Description 72

Mechanism of Action 72

R&D Progress 72

bevacizumab-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

BG-00001-Drug Profile 79

Product Description 79

Mechanism of Action 79

R&D Progress 79

BMS-986148-Drug Profile 80

Product Description 80

Mechanism of Action 80

R&D Progress 80

BNC-105-Drug Profile 81

Product Description 81

Mechanism of Action 81

R&D Progress 81

CBP-501-Drug Profile 83

Product Description 83

Mechanism of Action 83

R&D Progress 83

Cell Therapy 1 for Oncology-Drug Profile 85

Product Description 85

Mechanism of Action 85

R&D Progress 85

Cell Therapy for Malignant Pleural Mesothelioma and Advanced Leukemia-Drug Profile 86

Product Description 86

Mechanism of Action 86

R&D Progress 86

CRS-207-Drug Profile 87

Product Description 87

Mechanism of Action 87

R&D Progress 87

FP-1039-Drug Profile 90

Product Description 90

Mechanism of Action 90

R&D Progress 90

ganetespib-Drug Profile 92

Product Description 92

Mechanism of Action 92

R&D Progress 92

GEN-0101-Drug Profile 96

Product Description 96

Mechanism of Action 96

R&D Progress 96

Gene Therapy for Malignant Pleural Mesothelioma-Drug Profile 98

Product Description 98

Mechanism of Action 98

R&D Progress 98

Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma-Drug Profile 99

Product Description 99

Mechanism of Action 99

R&D Progress 99

GLONC-1-Drug Profile 100

Product Description 100

Mechanism of Action 100

R&D Progress 100

GSK-2256098-Drug Profile 103

Product Description 103

Mechanism of Action 103

R&D Progress 103

HSV-1716-Drug Profile 104

Product Description 104

Mechanism of Action 104

R&D Progress 104

iCasp9M28z-Drug Profile 107

Product Description 107

Mechanism of Action 107

R&D Progress 107

JTCR-016-Drug Profile 108

Product Description 108

Mechanism of Action 108

R&D Progress 108

MesoCancerVac-Drug Profile 109

Product Description 109

Mechanism of Action 109

R&D Progress 109

MesoCART-Drug Profile 110

Product Description 110

Mechanism of Action 110

R&D Progress 110

Monoclonal Antibody Conjugated to Target Mesothelin for Oncology-Drug Profile 111

Product Description 111

Mechanism of Action 111

R&D Progress 111

napabucasin-Drug Profile 113

Product Description 113

Mechanism of Action 113

R&D Progress 113

NGR-hTNF-Drug Profile 116

Product Description 116

Mechanism of Action 116

R&D Progress 116

nintedanib-Drug Profile 120

Product Description 120

Mechanism of Action 120

R&D Progress 120

nivolumab-Drug Profile 125

Product Description 125

Mechanism of Action 125

R&D Progress 125

pegargiminase-Drug Profile 132

Product Description 132

Mechanism of Action 132

R&D Progress 132

pembrolizumab-Drug Profile 136

Product Description 136

Mechanism of Action 136

R&D Progress 136

porfimer sodium-Drug Profile 145

Product Description 145

Mechanism of Action 145

R&D Progress 145

rAd-IFN-Drug Profile 147

Product Description 147

Mechanism of Action 147

R&D Progress 147

Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Metastatic Lung Cancer-Drug Profile 149

Product Description 149

Mechanism of Action 149

R&D Progress 149

TargomiRs-Drug Profile 150

Product Description 150

Mechanism of Action 150

R&D Progress 150

tivantinib-Drug Profile 152

Product Description 152

Mechanism of Action 152

R&D Progress 152

trabectedin-Drug Profile 154

Product Description 154

Mechanism of Action 154

R&D Progress 154

tremelimumab-Drug Profile 159

Product Description 159

Mechanism of Action 159

R&D Progress 159

TroVax-Drug Profile 161

Product Description 161

Mechanism of Action 161

R&D Progress 161

VS-5584-Drug Profile 164

Product Description 164

Mechanism of Action 164

R&D Progress 164

Malignant Pleural Mesothelioma-Recent Pipeline Updates 166

Malignant Pleural Mesothelioma-Dormant Projects 236

Malignant Pleural Mesothelioma-Discontinued Products 237

Malignant Pleural Mesothelioma-Product Development Milestones 238

Featured News & Press Releases 238

Sep 26, 2015: Aduro Biotech Announces Phase 1b Mesothelioma Trial Featured in Spotlight Poster at ESMO/ECC 238

Sep 09, 2015: Five Prime Therapeutics Announces Initial Data From Ongoing Phase 1b Trial of FP-1039 in Squamous Non Small Cell Lung Cancer and Mesothelioma 238

May 14, 2015: PharmaMar announces new advances in oncology at ASCO 2015 for its compound YONDELIS in small cell lung cancer, soft tissue sarcoma, and mesothelioma 239

Apr 23, 2015: Mesothelioma Immunotherapy Vaccine Receives Orphan Drug Designation from FDA, Baron & Budd Reports 241

Apr 19, 2015: Early Findings with KEYTRUDA (pembrolizumab), Mercks Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting 241

Apr 19, 2015: Immunotherapy drug pembrolizumab shows promise for mesothelioma patients 242

Mar 26, 2015: Aduro Receives Orphan Drug Designation for CRS-207 in Mesothelioma 243

Mar 18, 2015: New Data Investigating Mercks KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015 243

Jan 20, 2015: Verastem Doses First Patient In Phase 1 Clinical Trial Evaluating VS-5584 In Combination With VS-6063 In Mesothelioma 245

Jan 20, 2015: Verastem Receives Orphan Medicinal Product Designation from the European Commission for VS-5584 in Mesothelioma 245

Appendix 247

Methodology 247

Coverage 247

Secondary Research 247

Primary Research 247

Expert Panel Validation 247

Contact Us 247

Disclaimer 24

List of Tables

Number of Products under Development for Malignant Pleural Mesothelioma, H2 2015 12

Number of Products under Development for Malignant Pleural Mesothelioma-Comparative Analysis, H2 2015 13

Number of Products under Development by Companies, H2 2015 15

Number of Products under Investigation by Universities/Institutes, H2 2015 16

Comparative Analysis by Late Stage Development, H2 2015 17

Comparative Analysis by Clinical Stage Development, H2 2015 18

Comparative Analysis by Early Stage Development, H2 2015 19

Products under Development by Companies, H2 2015 20

Products under Development by Companies, H2 2015 (Contd...1) 21

Products under Development by Companies, H2 2015 (Contd...2) 22

Products under Investigation by Universities/Institutes, H2 2015 23

Malignant Pleural Mesothelioma-Pipeline by Aduro BioTech, Inc., H2 2015 24

Malignant Pleural Mesothelioma-Pipeline by Advantagene, Inc., H2 2015 25

Malignant Pleural Mesothelioma-Pipeline by Amphera BV, H2 2015 26

Malignant Pleural Mesothelioma-Pipeline by AnGes MG, Inc., H2 2015 27

Malignant Pleural Mesothelioma-Pipeline by ArQule, Inc., H2 2015 28

Malignant Pleural Mesothelioma-Pipeline by Bayer AG, H2 2015 29

Malignant Pleural Mesothelioma-Pipeline by Biogen, Inc., H2 2015 30

Malignant Pleural Mesothelioma-Pipeline by Bionomics Limited, H2 2015 31

Malignant Pleural Mesothelioma-Pipeline by Boehringer Ingelheim GmbH, H2 2015 32

Malignant Pleural Mesothelioma-Pipeline by Boston Biomedical, Inc., H2 2015 33

Malignant Pleural Mesothelioma-Pipeline by Bristol-Myers Squibb Company, H2 2015 34

Malignant Pleural Mesothelioma-Pipeline by CanBas Co., Ltd., H2 2015 35

Malignant Pleural Mesothelioma-Pipeline by Concordia Healthcare Corp., H2 2015 36

Malignant Pleural Mesothelioma-Pipeline by EnGeneIC Ltd, H2 2015 37

Malignant Pleural Mesothelioma-Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 38

Malignant Pleural Mesothelioma-Pipeline by Five Prime Therapeutics, Inc., H2 2015 39

Malignant Pleural Mesothelioma-Pipeline by Genelux Corporation, H2 2015 40

Malignant Pleural Mesothelioma-Pipeline by GlaxoSmithKline Plc, H2 2015 41

Malignant Pleural Mesothelioma-Pipeline by Juno Therapeutics Inc., H2 2015 42

Malignant Pleural Mesothelioma-Pipeline by MedImmune, LLC, H2 2015 43

Malignant Pleural Mesothelioma-Pipeline by Merck & Co., Inc., H2 2015 44

Malignant Pleural Mesothelioma-Pipeline by MolMed S.p.A., H2 2015 45

Malignant Pleural Mesothelioma-Pipeline by Morphotek, Inc., H2 2015 46

Malignant Pleural Mesothelioma-Pipeline by Novartis AG, H2 2015 47

Malignant Pleural Mesothelioma-Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 48

Malignant Pleural Mesothelioma-Pipeline by Oxford BioMedica Plc, H2 2015 49

Malignant Pleural Mesothelioma-Pipeline by Pfizer Inc., H2 2015 50

Malignant Pleural Mesothelioma-Pipeline by Pharma Mar, S.A., H2 2015 51

Malignant Pleural Mesothelioma-Pipeline by Polaris Pharmaceuticals, Inc., H2 2015 52

Malignant Pleural Mesothelioma-Pipeline by Synta Pharmaceuticals Corp., H2 2015 53

Malignant Pleural Mesothelioma-Pipeline by Verastem, Inc., H2 2015 54

Malignant Pleural Mesothelioma-Pipeline by Virttu Biologics Limited, H2 2015 55

Assessment by Monotherapy Products, H2 2015 56

Number of Products by Stage and Target, H2 2015 58

Number of Products by Stage and Mechanism of Action, H2 2015 60

Number of Products by Stage and Route of Administration, H2 2015 62

Number of Products by Stage and Molecule Type, H2 2015 64

Malignant Pleural Mesothelioma Therapeutics-Recent Pipeline Updates, H2 2015 166

Malignant Pleural Mesothelioma-Dormant Projects, H2 2015 236

Malignant Pleural Mesothelioma-Discontinued Products, H2 2015 237

List of Figures

Number of Products under Development for Malignant Pleural Mesothelioma, H2 2015 12

Number of Products under Development for Malignant Pleural Mesothelioma-Comparative Analysis, H2 2015 13

Number of Products under Development by Companies, H2 2015 14

Number of Products under Investigation by Universities/Institutes, H2 2015 16

Comparative Analysis by Clinical Stage Development, H2 2015 18

Assessment by Monotherapy Products, H2 2015 56

Number of Products by Top 10 Targets, H2 2015 57

Number of Products by Stage and Top 10 Targets, H2 2015 57

Number of Products by Top 10 Mechanism of Actions, H2 2015 59

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 59

Number of Products by Top 10 Routes of Administration, H2 2015 61

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 61

Number of Products by Top 10 Molecule Types, H2 2015 63

Number of Products by Stage and Top 10 Molecule Types, H2 2015 63

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Aduro BioTech, Inc.

Advantagene, Inc.

Amphera BV

AnGes MG, Inc.

ArQule, Inc.

Bayer AG

Biogen, Inc.

Bionomics Limited

Boehringer Ingelheim GmbH

Boston Biomedical, Inc.

Bristol-Myers Squibb Company

CanBas Co., Ltd.

Concordia Healthcare Corp.

EnGeneIC Ltd

F. Hoffmann-La Roche Ltd.

Five Prime Therapeutics, Inc.

Genelux Corporation

GlaxoSmithKline Plc

Juno Therapeutics Inc.

MedImmune, LLC

Merck & Co., Inc.

MolMed S.p.A.

Morphotek, Inc.

Novartis AG

Ono Pharmaceutical Co., Ltd.

Oxford BioMedica Plc

Pfizer Inc.

Pharma Mar, S.A.

Polaris Pharmaceuticals, Inc.

Synta Pharmaceuticals Corp.

Verastem, Inc.

Virttu Biologics Limited

Malignant Pleural Mesothelioma Therapeutic Products under Development, Key Players in Malignant Pleural Mesothelioma Therapeutics, Malignant Pleural Mesothelioma Pipeline Overview, Malignant Pleural Mesothelioma Pipeline, Malignant Pleural Mesothelioma Pipeline Assessment

select a license

Single User License
USD 2000 INR 143760
Site License
USD 4000 INR 287520
Corporate User License
USD 6000 INR 431280



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]